pING-HER3 Vaccine for Cancer

What is the Purpose of this Study?

If you choose to do this study, you will:

- Get the study vaccine three times over 8 weeks
- Have occasional blood draws for 5 years
- Have a biopsy to collect tumor tissue, if necessary
What is the Condition Being Studied?
Cancer

Who Can Participate in this Study?

People who:

- Have the one of the following cancers:

--Breast

--Colon

--Lung

--Prostate

--Ovarian

--Cervical

--Endometrial

--Gastric (stomach)

--Pancreatic

--Bladder

--Head and neck

--Liver

--Esophageal

- Have been treated with surgery and/or chemotherapy and radiation

- Have a protein called HER3 in the cancer cells

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.

Study Details

Full Title
ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH
RESECTED MALIGNANCIES
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00104093

NCT:
NCT03832855
ClinicalTrials.gov
View on ClinicalTrials.gov